Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. https://doi.org/10.1200/JCO.2008.20.1293

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA (2024) NCCN guidelines® Insights: Kidney cancer, Version 2.2024. J Natl Compr Canc Netw 22(1):4–16. https://doi.org/10.6004/jnccn.2024.0008

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. https://doi.org/10.1056/NEJMoa065044

Article  CAS  PubMed  Google Scholar 

Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Pitman Lowenthal S, Lee SY (2015) Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol 45(6):576–583. https://doi.org/10.1093/jjco/hyv045

Article  PubMed  PubMed Central  Google Scholar 

Speed B, Bu HZ, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, Kang P (2012) Pharmacokinetics, distribution, and metabolism of [14 C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos 40(3):539–555. https://doi.org/10.1124/dmd.111.042853

Article  CAS  PubMed  Google Scholar 

Takenaka M, Takahashi Y, Yashima H, Araki T, Yamamoto K (2019) The Impact of Sunitinib N-oxide as a Photodegradation Product of Sunitinib. Indonesian J Pharm 1(1):19–25. https://doi.org/10.24198/idjp.v1i1.19908

Article  Google Scholar 

Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66(2):357–371. https://doi.org/10.1007/s00280-009-1170-y

Article  CAS  PubMed  Google Scholar 

Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, Okada Y, Kawauchi A, Onishi H, Hira D, Morita SY, Terada T (2015) Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 13(4):350–358. https://doi.org/10.1016/j.clgc.2015.01.007

Article  PubMed  Google Scholar 

Numakura K, Fujiyama N, Takahashi M, Igarashi R, Tsuruta H, Maeno A, Huang M, Saito M, Narita S, Inoue T, Satoh S, Tsuchiya N, Niioka T, Miura M, Habuchi T (2018) Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. Oncotarget 9(38):25277–25284. https://doi.org/10.18632/oncotarget.25423

Article  PubMed  PubMed Central  Google Scholar 

Sabanathan D, Zhang A, Fox P, Coulter S, Gebski V, Balakrishnar B, Chan M, Liddle C, Gurney H (2017) Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring. Cancer Chemother Pharmacol 80(2):385–393. https://doi.org/10.1007/s00280-017-3362-1

Article  CAS  PubMed  Google Scholar 

Lankheet NAG, Knapen LM, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2014) Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit 36(3):326–334. https://doi.org/10.1097/FTD.0000000000000004

Article  CAS  PubMed  Google Scholar 

Takasaki S, Kawasaki Y, Kikuchi M, Tanaka M, Suzuka M, Noda A, Sato Y, Yamashita S, Mitsuzuka K, Saito H, Ito A, Yamaguchi H, Arai Y, Mano N (2018) Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma. Int J Clin Oncol 23(5):936–943. https://doi.org/10.1007/s10147-018-1302-7

Article  CAS  PubMed  Google Scholar 

Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 77(4):441–464. https://doi.org/10.1007/s00228-020-03014-8

Article  PubMed  Google Scholar 

Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102(5):765–776. https://doi.org/10.1002/cpt.787

Article  PubMed  PubMed Central  Google Scholar 

Cabel L, Blanchet B, Thomas-Schoemann A, Huillard O, Bellesoeur A, Cessot A, Giroux J, Boudou-Rouquette P, Coriat R, Vidal M, Saidu NEB, Golmard L, Alexandre J, Goldwasser F (2018) Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundam Clin Pharmacol 32(1):98–107. https://doi.org/10.1111/fcp.12327

Article  CAS  PubMed  Google Scholar 

Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55(4):379–386. https://doi.org/10.1007/s00280-004-0876-0

Article  CAS  PubMed  Google Scholar 

Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F (2012) Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 30(5):2046–2049. https://doi.org/10.1007/s10637-011-9764-8

Article  CAS  PubMed  Google Scholar 

Fukudo M, Ito T, Mizuno T, Shinsako K, Hatano E, Uemoto S, Kamba T, Yamasaki T, Ogawa O, Seno H, Chiba T, Matsubara K (2014) Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet 53(2):185–196. https://doi.org/10.1007/s40262-013-0108-z

Article  CAS  PubMed  Google Scholar 

Ishikawa Y, Araki T, Sato MT, Yashima H, Nagano D, Yamamoto K (2021) Development of a quantitative method for sunitinib N-oxide. Indo J Pharm 3(2). https://doi.org/10.24198/idjp.v3i2.37368

Kim A, Balis FM, Widemann BC (2009) Sorafenib and sunitinib. Oncologist 14(8):800–805. https://doi.org/10.1634/theoncologist.2009-0088

Article  CAS  PubMed  Google Scholar 

Wang J, Cui X, Cheng C, Wang Y, Sun W, Huang CK, Chen RJ, Wang Z (2021) Effects of CYP3A inhibitors ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of sunitinib and its main metabolite in rats. Chem Biol Interact 338:109426. https://doi.org/10.1016/j.cbi.2021.109426

Article  CAS  PubMed  Google Scholar 

Burger H, van Tol H, Brok M, Wiemer EAC, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K (2005) Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4(7):747–752. https://doi.org/10.4161/cbt.4.7.1826

Article  CAS  PubMed  Google Scholar 

Poirier JM, Cheymol G (1998) Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 35:461–473. https://doi.org/10.2165/00003088-199835060-00004

Article  CAS  PubMed  Google Scholar 

van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, Brouwers J, Aerts JG, van Gelder T, Mathijssen RHJ (2017) Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. Clin Pharmacokinet 56(7):683–688. https://doi.org/10.1007/s40262-016-0503-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, Ware JA (2012) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 92(2):203–213. https://doi.org/10.1038/clpt.2012.73

Article  CAS  PubMed  Google Scholar 

Raoul JL, Edeline J, Simmet V, Moreau-Bachelard C, Gilabert M, Frénel JS (2022) Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Cancers (Basel) 14(5):1156. https://doi.org/10.3390/cancers14051156

Article  CAS  PubMed